basal-like/triple negative breast cancer

(redirected from Triple Negative Breast Cancer)
Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to Triple Negative Breast Cancer: PubMed

basal-like/triple negative breast cancer

A recently recognised group of aggressive breast cancers for which there is no standard definition. The Notttingham group defines it as a breast cancer with expression of high-molecular weight (basal) cytokeratins CK 5/6, CK14, CK17.

Significance
Basal-like/triple negative breast cancers account for 12 to 17% of all breast cancers. They are more common in younger black and Hispanic women who are carriers of BRCA1 mutation, and are common ‘interval cancers’. They have a shorter overall survival and disease-free interval in node-negative and node-positive disease, and more often metastasise to the brain and lung.
References in periodicals archive ?
Keywords: Clinicopathological characteristics, Triple negative breast cancer.
Using a Pearson Chi-Squared test, patients presenting with triple negative breast cancer were compared to non-triple negative disease showing no correlation between family history and the incidence of TNBC (p value = 0.
Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behavior of triple negative breast cancer cells.
Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates.
An international team of 59 scientists, including four from Vancouver-based Simon Fraser University (SFU), had this discovery after carrying out the largest genetic analysis of what were thought to be triple negative breast cancer tumors.
Final efficacy and safety results of a randomized phase II study of the PARP nhibitor iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC).
Recently, BiPar announced positive interim safety data from an ongoing Phase 2 clinical trial of the company's PARP inhibitor, BSI-201, in combination with chemotherapy in patients with metastatic triple negative breast cancer (TNBC).
M2 PHARMA-February 13, 2018-Erytech names triple negative breast cancer as next indication for eryaspase
M2 EQUITYBITES-February 13, 2018-Erytech names triple negative breast cancer as next indication for eryaspase
Based on these promising results, Pluristem conducted a pre-clinical study of female mice harboring human triple negative breast cancer, or TNBC.
The study by Dr Alan Prem Kumar from the Cancer Science Institute of Singapore (CSI Singapore) at NUS and NUS Yong Loo Lin School of Medicine, together with Professor Shazib Pervaiz and Associate Professor Marie-Veronique Clement from NUS Yong Loo Lin School of Medicine, found that high levels of Manganese Superoxide Dismutase (MnSOD), a key enzyme involved in regulating the cellular redox milieu, has a role to play in causing breast cancer cells to turn aggressive, especially in triple negative breast cancer subtype tumours.